BLGO vs. VOXR, AREC, ASM, NB, GAMC, TRX, HYMC, LOOP, USGO, and NMG
Should you be buying BioLargo stock or one of its competitors? The main competitors of BioLargo include Vox Royalty (VOXR), American Resources (AREC), Avino Silver & Gold Mines (ASM), NioCorp Developments (NB), Golden Arrow Merger (GAMC), TRX Gold (TRX), Hycroft Mining (HYMC), Loop Industries (LOOP), U.S. GoldMining (USGO), and Nouveau Monde Graphite (NMG).
Vox Royalty (NASDAQ:VOXR) and BioLargo (NASDAQ:BLGO) are both small-cap basic materials companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, community ranking, institutional ownership, valuation, media sentiment and dividends.
In the previous week, Vox Royalty had 1 more articles in the media than BioLargo. MarketBeat recorded 3 mentions for Vox Royalty and 2 mentions for BioLargo. BioLargo's average media sentiment score of 0.89 beat Vox Royalty's score of 0.63 indicating that Vox Royalty is being referred to more favorably in the media.
Vox Royalty presently has a consensus target price of $3.00, suggesting a potential upside of 31.87%. Given BioLargo's higher possible upside, research analysts clearly believe Vox Royalty is more favorable than BioLargo.
Vox Royalty has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, BioLargo has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.
Vox Royalty has a net margin of 2.93% compared to Vox Royalty's net margin of 0.00%. BioLargo's return on equity of 2.76% beat Vox Royalty's return on equity.
46.0% of Vox Royalty shares are owned by institutional investors. Comparatively, 0.0% of BioLargo shares are owned by institutional investors. 19.0% of BioLargo shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
BioLargo has lower revenue, but higher earnings than Vox Royalty. BioLargo is trading at a lower price-to-earnings ratio than Vox Royalty, indicating that it is currently the more affordable of the two stocks.
BioLargo received 109 more outperform votes than Vox Royalty when rated by MarketBeat users. Likewise, 60.99% of users gave BioLargo an outperform vote while only 50.00% of users gave Vox Royalty an outperform vote.
Summary
Vox Royalty beats BioLargo on 12 of the 15 factors compared between the two stocks.
Get BioLargo News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLargo Competitors List
Related Companies and Tools
